Nazofarenks Kanserinde EBV DNA Rehberliğinde Tedavi Yönetimi

Authors

Ali Alkan

References

Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80.doi:10.1016/S0140-6736(19)30956-0

Chua MLK, Zhang X, Wong KCW, et al. Updates on Treatments and Management of Nasopharyngeal Carcinoma. Am Soc Clin Oncol Educ Book. 2025;45(3):e472460.doi:10.1200/EDBK-25-472460

Chan KCA, Woo JKS, King A, et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017;377(6):513-22.doi:10.1056/NEJMoa1701717

Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461-70.doi:10.1056/NEJMoa032260

Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19(8):2208-15.doi:10.1158/1078-0432.CCR-12-3702

Han BL, Xu XY, Zhang CZ, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev. 2012;13(6):2577-81.doi:10.7314/apjcp.2012.13.6.2577

Pajak W, Kleinrok J, Pec J, et al. Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives. Life (Basel). 2026;16(5).doi:10.3390/life16050764

Wong KCW, Hui EP, Lo KW, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679-95.doi:10.1038/s41571-021-00524-x

Yu KJ, Hsu WL, Pfeiffer RM, et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res. 2011;17(7):1906-14.doi:10.1158/1078-0432.CCR-10-1681

Lam WKJ, King AD, Miller JA, et al. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. J Natl Cancer Inst. 2023;115(4):355-64.doi:10.1093/jnci/djad012

Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41(11):1195-227.doi:10.1002/cac2.12218

Tang LL, Chen YP, Mao YP, et al. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017;15(7):913-9.doi:10.6004/jnccn.2017.0121

Lee VH, Kwong DL, Leung TW, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer. 2019;144(7):1713-22.doi:10.1002/ijc.31856

Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004;22(15):3053-60.doi:10.1200/JCO.2004.05.178

Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25(6):1204-8.doi:10.1093/annonc/mdu117

Liu LT, Tang LQ, Chen QY, et al. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862-9.doi:10.1016/j.ijrobp.2015.08.003

Lu X, Zhu L, Tan B, et al. Early circulating EBV-DNA clearance predicts enhanced short-term treatment response and survival benefit in locally advanced nasopharyngeal carcinoma. BMC Cancer. 2025;25(1):1499.doi:10.1186/s12885-025-14888-1

Zhang W, Chen Y, Chen L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore). 2015;94(20):e845.doi:10.1097/MD.0000000000000845

Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol. 2018:JCO2018777847.doi:10.1200/JCO.2018.77.7847

Liu SL, Li XY, Yang JH, et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2024;25(12):1563-75.doi:10.1016/S1470-2045(24)00504-7

Li XY, Luo DH, Guo L, et al. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. J Clin Oncol. 2022;40(11):1163-73.doi:10.1200/JCO.21.01467

Tang LL, Guo R, Zhang N, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728-36.doi:10.1001/jama.2022.13997

Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303-13.doi:10.1016/S0140-6736(21)01123-5

Miao J, Wang L, Tan SH, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022;8(12):1776-85.doi:10.1001/jamaoncol.2022.4656

Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21-9.doi:10.1016/j.ijrobp.2014.01.052

Huang CL, Wang GY, Lou JH, et al. Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up. Radiother Oncol. 2024;190:110032.doi:10.1016/j.radonc.2023.110032

Sun Y, Ma J, Lyu J-W, et al. Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial. Journal of Clinical Oncology. 2025;43(16_suppl):6010-.doi:10.1200/JCO.2025.43.16_suppl.6010

Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16(3):1016-24.doi:10.1158/1078-0432.CCR-09-2796

Hsu CL, Chang KP, Lin CY, et al. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2012;34(8):1064-70.doi:10.1002/hed.21890

Zhang Y, Tang LL, Li YQ, et al. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis. Int J Cancer. 2019;144(9):2313-9.doi:10.1002/ijc.32021

Chen FP, Huang XD, Lv JW, et al. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer. 2020;126(10):2163-73.doi:10.1002/cncr.32770

Neo J, Ong EHW, Zhang X, et al. Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database. Eur J Cancer. 2025;220:115396.doi:10.1016/j.ejca.2025.115396

He Q, Huang Y, Yuan L, et al. A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China. Sci Rep. 2023;13(1):11700.doi:10.1038/s41598-023-38396-z

Economopoulou P, Pantazopoulos A, Spathis A, et al. Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions. Cells. 2021;11(1).doi:10.3390/cells11010032

Published

November 16, 2026

License

License